Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation.

Nature Communications
Hemalvi PataniGabriella Ficz

Abstract

Epigenetic reprogramming is a cancer hallmark, but how it unfolds during early neoplastic events and its role in carcinogenesis and cancer progression is not fully understood. Here we show that resetting from primed to naïve human pluripotency results in acquisition of a DNA methylation landscape mirroring the cancer DNA methylome, with gradual hypermethylation of bivalent developmental genes. We identify a dichotomy between bivalent genes that do and do not become hypermethylated, which is also mirrored in cancer. We find that loss of H3K4me3 at bivalent regions is associated with gain of methylation. Additionally, we observe that promoter CpG island hypermethylation is not restricted solely to emerging naïve cells, suggesting that it is a feature of a heterogeneous intermediate population during resetting. These results indicate that transition to naïve pluripotency and oncogenic transformation share common epigenetic trajectories, which implicates reprogramming and the pluripotency network as a central hub in cancer formation.

References

Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Apr 19, 2003·Science·Amir EdenRudolf Jaenisch
Dec 24, 2004·The EMBO Journal·Carmen BrennerFrançois Fuks
Dec 17, 2005·Nature·Emmanuelle ViréFrançois Fuks
Dec 22, 2005·Nature Reviews. Genetics·Andrew P FeinbergSteven Henikoff
Jan 21, 2006·Cancer Research·Kam-Wing JairKornel E Schuebel
Jan 4, 2007·Nature Genetics·Martin WidschwendterPeter W Laird
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
May 30, 2008·Nature·Tarjei S MikkelsenAlexander Meissner
Jan 10, 2009·Nature Protocols·Da Wei HuangRichard A Lempicki
May 22, 2009·Nucleic Acids Research·Timothy L BaileyWilliam S Noble
Sep 1, 2009·Epigenetics : Official Journal of the DNA Methylation Society·Margaret RushMatthew C Lorincz
Sep 30, 2009·Epigenetics : Official Journal of the DNA Methylation Society·Eric HervouetPierre-François Cartron
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 28, 2011·Nature Genetics·Kasper Daniel HansenAndrew P Feinberg
Sep 24, 2011·Nature Reviews. Cancer·Stephen B Baylin, Peter A Jones
Mar 7, 2012·Genome Research·Hariharan EaswaranStephen B Baylin
Mar 30, 2012·Nature·Zachary D SmithAlexander Meissner
Sep 8, 2012·Nature·UNKNOWN ENCODE Project Consortium
Dec 25, 2012·Cell·Jose M PoloKonrad Hochedlinger
Jan 24, 2013·Briefings in Functional Genomics·Duncan Sproul, Richard R Meehan
Aug 13, 2013·Nature Structural & Molecular Biology·Liying YanFuchou Tang
Sep 28, 2013·Nature Genetics·UNKNOWN Cancer Genome Atlas Research NetworkJoshua M Stuart
Oct 11, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Scott J DiedeStephen J Tapscott
Aug 1, 2014·Nature·Hongshan GuoJie Qiao
Sep 3, 2014·Genomics·Gabriella Ficz, John G Gribben
Oct 16, 2015·Molecular Biology and Evolution·Han Chen, Xionglei He
Oct 22, 2015·Development·Paul BlakeleyKathy K Niakan

❮ Previous
Next ❯

Methods Mentioned

BETA
ChIP-seq
RNA-seq
Flow cytometry
electrophoresis
PCR
immunoprecipitation
Assay
fluorescence-activated cell sorting
FACS

Software Mentioned

Genome browser
ChromHMM
Bioconductor
ChAMP
Mascot
Prism
FeatureCounts
R
Mascot Distiller
Methprimer

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.